Long-Term Outcomes in Five Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Treated with Molgramostim Nebulizer Solution

Footnotes

This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.

Conflict of interest: Georg Sterniste reports receiving support for the present manuscript from Savara.

Conflict of interest: Celia Montana reports receiving support for the present manuscript from Savara.

Conflict of interest: Macel Veltkamp reports receiving support for the present manuscript from Savara.

Conflict of interest: Ida Rønnov-Jessen reports receiving support for the present manuscript from Savara.

Conflict of interest: Arschang Valipour reports receiving support for the present manuscript from Savara.

Conflict of interest: Sara Salgado reports receiving support for the present manuscript from Savara.

Conflict of interest: MARIA MOLINA MOLINA reports receiving support for the present manuscript from Savara. Grants received from Boehringer Ing, outside the submitted work; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events for Boehringer Ing, Roche, Ferrer, Janssen, outside the submitted work; Support for attending meetings and/or travel from Boehringer Ing, outside the submitted work.

Conflict of interest: Elisabeth Bendstrup reports receiving support for the present manuscript from Savara. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Boehringer Ingelheim, Hofmann la Roche, and Daiichi-Sankyo & Astra Zeneca, outside the submitted work; Support for attending meetings and/or travel from Boehringer Ingelheim, outside the submitted work; Participation on a Data Safety Monitoring Board or Advisory Board for Boehringer Ingelheim, Veracyte, and Simbec, outside the submitted work.